RPL19A Antibody

What is RPL19 and what is its biological function?

RPL19, also known as 60S ribosomal protein L19, is a component of the large ribosomal subunit. It plays a crucial role in the ribonucleoprotein complex responsible for protein synthesis in cells. The ribosomal protein is involved in mRNA translation and has been studied extensively in various research contexts. RPL19 has a calculated molecular weight of approximately 23 kDa, although it typically appears around 28 kDa in experimental observations due to post-translational modifications .

What are the primary applications for RPL19 antibodies in research?

RPL19 antibodies are utilized in multiple experimental applications, with validated uses including:

Research shows these applications have been validated in multiple tissue and cell types, including human and rodent samples .

What species reactivity do RPL19 antibodies typically demonstrate?

Most commercially available RPL19 antibodies show reactivity across human, mouse, and rat samples. This cross-reactivity stems from high sequence conservation of RPL19 among mammalian species. Specifically, antibodies like those from Proteintech (14701-1-AP) and Abcam (ab224592) have been experimentally validated with human and mouse samples, with rat reactivity also confirmed for some products .

What are the optimal sample preparation techniques for different RPL19 antibody applications?

For Western blotting with RPL19 antibodies, cells should be washed with PBS and lysed in RIPA buffer containing protease inhibitor cocktail and 1 mM PMSF. Protein concentration should be measured using BCA assay before loading onto 10% gels. For immunohistochemistry, paraffin-embedded tissues typically require antigen retrieval using TE buffer (pH 9.0) or citrate buffer (pH 6.0) before antibody incubation. For immunofluorescence, cells are generally fixed, permeabilized, and blocked before overnight incubation with primary antibody at concentrations between 1:50-1:500 .

What controls are essential when working with RPL19 antibodies?

When working with RPL19 antibodies, several controls are critical:

• Positive controls: HeLa cells, MCF-7 cells, mouse spleen tissue, and mouse testis tissue have been validated as positive controls for Western blotting

• Negative controls: Omitting primary antibody or using isotype control antibodies

• Loading controls: GAPDH is commonly used as a housekeeping gene control

• Technical validation: Verification of target protein size (28 kDa observed vs. 23 kDa calculated)

These controls help ensure specificity and reliability of experimental results, particularly when investigating novel tissue or cell types .

How should RPL19 antibody dilution be optimized for various experimental applications?

Optimization of RPL19 antibody dilution is critical for experimental success. While standard dilution ranges exist (see table in question 1.2), researchers should conduct titration experiments to determine optimal concentrations for their specific samples and experimental conditions. For Western blot, start with mid-range dilutions (1:1000) and adjust based on signal intensity and background. For immunohistochemistry, preliminary experiments with serial dilutions (1:20, 1:50, 1:100, 1:200) are recommended to determine optimal staining conditions. Sample-dependent variables such as expression level, fixation method, and detection system significantly impact optimal dilution .

How has RPL19 been utilized in the development of the TRAPKI-seq methodology?

The RPL19-TRAPKI-seq method represents an advanced application combining CRISPR/Cas9 knock-in and Translating Ribosome Affinity Purification (TRAP) technologies. This method enables precise investigation of translating mRNA populations and has been particularly valuable for elucidating mechanisms of action for natural products and small molecules.

In this approach, RPL19 was selected after screening eight ribosomal proteins for their efficiency in enriching ribosomal mRNA. RPL19 demonstrated superior enrichment efficiency compared to the traditionally used RPL10A. The method involves:

• CRISPR knock-in of an EGFP tag into the RPL19 genome

• Expression of EGFP-RPL19 fusion protein for ribosome tagging

• Affinity purification of tagged ribosomes and associated mRNAs

• Next-generation sequencing of the purified translating mRNAs

This system provides more specific information about actively translating mRNAs compared to total mRNA sequencing, allowing researchers to identify translational changes induced by compounds like rapamycin and SBF-1 .

What advantages does RPL19 offer over other ribosomal proteins in TRAP experiments?

Research has demonstrated that RPL19 exhibits significantly higher enrichment efficiency compared to other ribosomal proteins, including the traditionally used RPL10A. When screening multiple ribosomal proteins for TRAP methodology, RPL19 showed the most significant enrichment of target mRNAs.

In comparative experiments, RPL19 demonstrated enhanced sensitivity in detecting compound-induced RNA changes. For example, when cells were treated with thapsigargin (an ER stress inducer), TRAP using RPL19 showed a more pronounced increase in stress-response genes like CHOP (sevenfold increase in TRAP-purified RNA versus fivefold in total RNA). This suggests RPL19-based TRAP is more sensitive and rapid in detecting compound-induced RNA changes during specific time periods compared to total RNA analysis .

How can RPL19 antibodies be used to study translational regulation in different cellular contexts?

RPL19 antibodies can be employed in multiple experimental approaches to study translational regulation:

• Polysome profiling with immunoblotting: RPL19 antibodies can identify ribosome-associated mRNAs in different translational states (monosomes vs. polysomes)

• Ribosome footprinting combined with immunoprecipitation: This approach can reveal ribosome positioning and translational dynamics

• Stress response studies: As demonstrated in the RPL19-TRAPKI-seq research, RPL19 can be used to monitor translational changes during cellular stress responses, such as thapsigargin-induced ER stress

• Drug mechanism studies: RPL19-based approaches can reveal translational impacts of compounds like rapamycin, showing specific effects on translation and energy metabolism pathways

What are the implications of using RPL19 as a marker in studies of oxidative phosphorylation?

The RPL19-TRAPKI-seq method has revealed unexpected connections between translational regulation and oxidative phosphorylation. When investigating the anti-tumor compound SBF-1 (a 23-oxa-analog of natural saponin OSW-1), researchers found that SBF-1 significantly affected mitochondrial function.

RNA-Seq analysis utilizing RPL19-TRAP revealed downregulation of mitochondria-related genes and pathways involved in oxidative phosphorylation. Flow cytometry further demonstrated that SBF-1 significantly reduced mitochondrial oxygen consumption and membrane potential, suggesting disruption of mitochondrial respiration as its primary mode of action.

This application illustrates how RPL19-based approaches can connect translational regulation to unexpected cellular pathways, providing insights into drug mechanisms that might be missed by conventional approaches. The technique allows researchers to narrow down potential targets from complex natural products with previously unclear mechanisms of action .

What factors might affect the observed molecular weight of RPL19 in experimental results?

While the calculated molecular weight of RPL19 is approximately 23 kDa, it typically appears at around 28 kDa in experimental observations. This discrepancy can be attributed to several factors:

• Post-translational modifications (phosphorylation, glycosylation)

• Protein-protein interactions that are not fully disrupted during sample preparation

• The presence of fusion tags in recombinant or knock-in experiments (e.g., EGFP-RPL19)

• Incomplete denaturation during sample preparation

• Variations in gel composition and running conditions

Understanding these factors is critical for accurate interpretation of Western blot results. In EGFP-RPL19 knock-in experiments, for instance, the expected molecular weight would be significantly higher due to the added EGFP tag .

What are common issues encountered with RPL19 detection in immunohistochemistry?

Several technical challenges may arise when using RPL19 antibodies for immunohistochemistry:

• Antigen masking: RPL19 detection in fixed tissues often requires optimization of antigen retrieval methods. While TE buffer (pH 9.0) is suggested as the primary method, citrate buffer (pH 6.0) may serve as an alternative when results are suboptimal

• Background staining: Due to the ubiquitous expression of ribosomal proteins, non-specific background can be problematic. This can be mitigated through:

  • Optimizing antibody dilution (typically 1:20-1:200)

  • Extending blocking steps

  • Using more stringent washing procedures

• Tissue-specific optimization: Detection efficiency varies between tissues. For example, brain tissue (both human and mouse) has been validated for RPL19 detection, but other tissues may require protocol adjustments

• Fixation effects: Overfixation can mask epitopes, requiring extended antigen retrieval or alternative antibody clones .

How can specificity of RPL19 antibodies be verified in different experimental setups?

Verifying RPL19 antibody specificity is crucial for experimental validity. Several approaches are recommended:

• Molecular weight confirmation: Observing the expected band at approximately 28 kDa in Western blots

• Multiple application validation: Confirming RPL19 detection across different techniques (WB, IHC, IF) with consistent results

• Positive control validation: Testing the antibody on known positive samples (e.g., HeLa cells, MCF-7 cells, mouse brain tissue)

• Knockdown/knockout validation: Demonstrating reduced signal in samples where RPL19 expression has been diminished through siRNA or CRISPR approaches

• Peptide competition assays: Pre-incubating the antibody with the immunizing peptide should abolish specific staining

• Cross-reactivity testing: When using in multiple species, confirming appropriate molecular weight and localization patterns in each species .

How is RPL19 being used to study drug mechanisms of action in anti-cancer research?

RPL19-based approaches, particularly the RPL19-TRAPKI-seq method, are providing valuable insights into anti-cancer drug mechanisms. For example, researchers used this approach to investigate SBF-1, a 23-oxa-analog of the natural saponin OSW-1, which exhibits potent anti-tumor activity.

Using RPL19-TRAPKI-seq, researchers found that SBF-1's cytotoxic effects on tumor cells stem from disruption of cellular oxidative phosphorylation. The RNA-Seq analysis revealed significant downregulation of mitochondria-related genes and pathways involved in oxidative phosphorylation. These findings were validated by flow cytometry showing decreased mitochondrial oxygen consumption and membrane potential in treated cells.

This application demonstrates how RPL19-based approaches can reveal previously unidentified mechanisms of action for anti-cancer compounds, potentially accelerating therapeutic development .

What considerations are important when integrating RPL19 antibodies into multi-omics research approaches?

When integrating RPL19 antibodies into multi-omics research strategies, several considerations are essential:

• Compatibility with downstream applications: Ensure antibody formulations (particularly buffers and preservatives) are compatible with sensitive omics techniques

• Sample preparation harmonization: Develop protocols that allow parallel preparation of samples for different omics approaches

• Data integration strategies: Plan for bioinformatic approaches that can integrate data from RPL19-based translatomics with other omics layers (genomics, proteomics, metabolomics)

• Temporal considerations: Account for the different timescales of responses at transcriptional, translational, and post-translational levels

• Cellular heterogeneity: Consider cell-type specific effects when working with complex tissues or mixed cell populations

The RPL19-TRAPKI-seq method provides an excellent example of successful integration, combining genomic engineering (CRISPR knock-in), translatomics (TRAP), and next-generation sequencing to provide insights that wouldn't be possible with any single approach .